ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NVCN Neovasc Inc

30.03
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neovasc Inc NASDAQ:NVCN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 30.03 27.70 30.00 0 01:00:00

Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

24/02/2022 2:00pm

GlobeNewswire Inc.


Neovasc (NASDAQ:NVCN)
Historical Stock Chart


From Jul 2021 to Jul 2024

Click Here for more Neovasc Charts.

via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on March 10, 2022.

Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13726770. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at https://www.neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.

InvestorsMike CavanaughWestwicke/ICRPhone: +1.617.877.9641Mike.Cavanaugh@westwicke.com

MediaSean LeousWestwicke/ICRPhone: +1.646.866.4012Sean.Leous@icrinc.com

1 Year Neovasc Chart

1 Year Neovasc Chart

1 Month Neovasc Chart

1 Month Neovasc Chart

Your Recent History

Delayed Upgrade Clock